financetom
financetom
/
Terms and Conditions
Terms and Conditions for Website Use

1. Acceptance of Terms

By using this website, you agree to be bound by these terms and conditions, which we may update from time to time. If you do not agree to these terms and conditions, please do not use this website.

2. Use of Website Content

The content of this website, including but not limited to text, images, and videos, is protected by copyright and other intellectual property laws. You may view, download, or print the content for your personal use, but you may not republish, sell, or modify any of the content without the express written consent of the website operator.

3. Disclaimer of Liability

This website provides information and services free of charge, and we do not guarantee the accuracy, completeness, or timeliness of the content. We disclaim all liability for any errors or omissions in the content of this website. Use of this website is at your own risk.

4. Links to Other Websites

This website may contain links to other websites. We do not control or endorse the content of any linked websites, and we are not responsible for any transactions you may have with such websites.

5. No Spamming

You may not use this website to send spam or engage in any other unsolicited advertising or marketing activities. We reserve the right to terminate your access to this website if we determine that you are using it for spamming or other unauthorized purposes.

6. No Illegal Activities

You may not use this website for any illegal activities, including but not limited to accessing or disclosing personal information about others without their consent. Any violation of these terms and conditions may result in legal action against you.

Related Articles >
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
May 30, 2026
Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in maximally changed cognitive domain (MCCD) by 24 weeks, with a median maximal cognitive decline of -15.8% for NUBEQA versus -36.1% with enzalutamide (p=0.009) in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic castration-sensitive prostate cancer (mCSPC) in...
SoftBank to build up AI data centres in France with major investment
SoftBank to build up AI data centres in France with major investment
May 30, 2026
PARIS, May 30 (Reuters) - Japan's SoftBank Group will invest €45 billion over the next five years in a push to build up artificial intelligence infrastructure in France, founder Masayoshi Son told the paper La Tribune Dimanche in an interview published on Saturday. Son said the investment, described as the biggest of its kind so far in Europe, would be...
Mineralys' pill cuts blood pressure in kidney disease patients
Mineralys' pill cuts blood pressure in kidney disease patients
May 30, 2026
May 30 (Reuters) - Mineralys Therapeutics' ( MLYS ) experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented at a major European medical conference on Saturday. Chronic kidney disease affects more than 37 million Americans, according to the Centers for Disease Control and Prevention, and is closely tied to high blood pressure....
When the market is bad, we build: Inside Binance’s bold 2030 master plan
When the market is bad, we build: Inside Binance’s bold 2030 master plan
May 30, 2026
The crypto market is struggling, competitors are either passing through hard times or pivoting to other areas, while Binance is building with eyes on increasing its active user base ten-fold to 3 billion by 2030, Catherine Chen, the head of VIP and Institutional told CoinDesk in an interview. “It is true, the market is going through a hard time,” Chen...
Copyright 2023-2026 - www.financetom.com All Rights Reserved